Which CBD Company is Poised to Become the CVSI of 2019?

Is American Premium Water Corporation poised to become the next CV Sciences or New Age Beverage?

New York, NY -- April 29, 2019 -- InvestorsHub NewsWire -- SmallCapTips.com News Commentary --

The CBD market is growing into the mainstream on a daily basis. In March, CVS announced that it would be selling CBD infused products in eight states. Walgreens quickly followed suit, announcing one week later that it would be selling CBD infused products in 1500 of its stores. More big box retailers are expected to follow suit. Whole Foods has begun selling CBD products in select markets while Neiman Marcus and Sephora have begun selling CBD cosmetics. The FDA is expected to give guidance on CBD infused food and beverages at the end of May paving the way for further adaptation of CBD infused products.

New Age Beverages (NASDAQ: NBEV) recently announced that it would begin selling some its Marley branded teas in Wal-Mart, the US's biggest retailer. This distribution agreement positions them to have massive distribution once CBD is widely accepted by traditional retailers. The company also announced last week that it will be begin selling CBD infused topicals, creams, and lotions through a networks of independent distributors. The Company has taken steps to become a fully integrated CBD-infused product company, which had a monumental transformation from OTC penny stock in 2016 to being listed on the NASDAQ the following year. The Company has had increased interest and revenue growth since entering the CBD market last fall.

CV Sciences (OTC: CVSI) recently announced that it has hired Deloitte and Touche LLP, positioning the Company for an uplisting onto the NASDAQ with a Big-5 auditor. This comes after the Company posted $48.24m in revenue for 2018, a 133% increase from 2017. CVSI has established itself as the market leader in CBD oils and pharmaceuticals, and is poised to continue to grow into 2019. CVSI has had rapid price appreciation over the past year and half, when it was trading as low as $0.20 at the end of 2017 and has recently reached highs of $9.20.

Which company currently on the OTC is poised to follow a similar path? Puration, Inc (OTC: PURA) has established itself as one of the first company's to have produced a CBD-infused beverage. PURA received a price target of $0.25 from Goldman Research. Although they have established distribution, they have nowhere near the scale that NBEV had when it made the jump to the NASDAQ. Kona Gold Solutions, Inc (OTC: KGKG) has a similar profile to PURA. Both companies have not made any statements about potentially uplisting and both have not made any progress towards introducing products outside infused beverages like NBEV. Khiron Life Sciences Corporation (OTC: KHRNF) is well positioned for the CBD-infused cosmetics business in the South American market. They have made nice additions to their board of directors, but they are focused on the Latin American market, and have made no statements which direct them to enter the US market or introduce a beverage.

American Premium Water Corporation (OTC: HIPH) has positioned itself to be the next OTC to NASDAQ story and potentially rival NBEV as a market leader in the CBD-infused consumer products sector. HIPH introduced its infused CBD beverage in January 2018 during Super Bowl 52, nine months before NBEV announced that it was developing CBD infused beverages. Additionally HIPH entered the cosmetics business well before NBEV, having acquired Canyon Create in November and subsequently acquiring plant + body essentials last month. Both brands have functional cosmetics that infuse CBD into creams, lotions, topicals, and balms.

The Company's CEO, Ryan Fishoff has stated a desire on numerous occasions for the Company to become fully reporting and uplist to the NASDAQ. In a recent press release, where the HIPH issued FY 2019 guidance of $1 million, Mr. Fishoff stated that the Company continues To focus on uplisting and getting to the NASDAQ by 2020. Mr. Fishoff has also confirmed this is the Company is taking the steps to get fully reporting, tweeting recently he met with the auditing firm Weinberg & Co. He commented in another tweet that he expects the Company to retain them within 20-30 days. Becoming fully reporting combined with a diverse set of CBD infused products, HIPH is on the path to becoming viable for uplist to the NASDAQ to follow NBEV's path.

HIPH is currently priced at $0.03 but last week received financing at a $0.40 valuation. The Company has shown an ability to get exposure at highly visible events and has released an independent study that validates the Company's claims about its proprietary nano-technology. The Company has also expanded to Europe with a partnership with English brewery Hanlon's to make CBD infused beer using HIPH's proprietary nano-formulation. HIPH also stated they have received a significant order from a distributor in the UK, solidifying international distribution on top of growing US distribution. SmallCapTips views HIPH as a standout in the OTC amongst its peers but also a Company that could be battling NBEV within the near future for supremacy in the growing CBD consumer products business and potentially rivaling CVSI from a revenue perspective.

For commentary inquiries, please contact: info@smallcaptips.com

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SmallCap Tips undertakes no obligation to update such statements. SmallCap Tips was not compensated by (NASDAQ: NBEV), (OTC: HIPH), (OTC: KGKG), (OTC: PURA), (OTC: KHRNF) or any other company mentioned in this article, You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company.